Immune-related adverse events associated with immune checkpoint inhibitor therapy in bladder cancer patients: A systematic review and meta-analysis
Open Access
- 11 December 2025
- journal article
- review article
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 44 (2) , 79-91
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint InhibitorsJAMA Network Open, 2024
- Health‐related quality of life in survivors of advanced melanoma treated with anti‐PD1‐based immune checkpoint inhibitorsCancer Medicine, 2023
- Immune checkpoint Inhibitor–Induced diarrhea and Colitis: Incidence and Management. A systematic review and Meta-analysisCancer Treatment Reviews, 2022
- Cutaneous adverse events associated with immune checkpoint blockade: A systematic review and meta-analysisCritical Reviews in Oncology/Hematology, 2021
- Bladder CancerJAMA, 2020
- A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum‐resistant metastatic urothelial cancerCancer, 2020
- Lack of Transparency in Publishing Negative Clinical Trial ResultsClinics in Podiatric Medicine and Surgery, 2020
- Hepatotoxicity From Immune Checkpoint Inhibitors: A Systematic Review and Management RecommendationHepatology, 2020
- Immune Checkpoint Inhibitors-Induced Hepatitis2018
- Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor RegimensJAMA Oncology, 2018